A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants (HOMERUS)
HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer
Sponsor: Hoffmann-La Roche
Listed as NCT02040935, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 15 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Jul 2019 — Sep 2019 [monthly]
Completed PHASE3
-
Oct 2018 — Jul 2019 [monthly]
Completed PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .